Nuvectis Pharma (NVCT)
(Real Time Quote from BATS)
$6.60 USD
-0.07 (-1.05%)
Updated Sep 16, 2024 09:50 AM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
NVCT 6.60 -0.07(-1.05%)
Will NVCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVCT
Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)
NVCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 10th
Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep going
Zacks.com featured highlights Corsair Gaming, Nuvectis Pharma and WisdomTree
Other News for NVCT
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Nuvectis Pharma announces U.S. FDA granted ODD for NXP800
Nuvectis gains on FDA’s orphan drug designation for cancer therapy
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers